Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $76.00.

Shares of Verona Pharma stock opened at $60.26 on Wednesday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. Verona Pharma has a twelve month ...

SHANGHAI, Feb. 7, 2025 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster. The first-in-class dual ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Getting addicted, no pun intended, to an animated conspiracy thriller from Adult Swim ...

Sanofi S.A. Part Cert 0.02% €8.03M ...